0

Explore original, structured summaries for research and education.

Research profile

Sermorelin(Sermorelin acetate)

(Sermorelin acetate)

Sermorelin(Sermorelin acetate) is indexed as a GHRH analog research entry. Its current evidence category is (Sermorelin acetate), and published discussion commonly places it within Growth Hormone, Weight Loss. This profile summarizes identifiers and literature signals; it does not provide treatment or dosing advice.

Growth HormoneWeight Loss

Identity

Molecular Data

Molecular weight
3,358 Da
Chain length
29 amino acids
Type
GHRH analog
Reported half-life
10-12 minutes

Literature map

Research indications

Muscle Growth

  • Lean Body Mass Enhancementmost effective
  • IGF-1 Mediated Growtheffective
  • Athletic Recoveryeffective

Anti-Aging

  • Age-Related GH Decline Reversaleffective
  • Body Composition Improvementeffective
  • Skin Quality Enhancementmoderate

Hormonal

  • Endogenous GH Stimulationmoderate
  • Natural Pulsatile Secretionmoderate

Evidence-gated guidance

Dosing Protocols

No established human dosing protocol is recognized for this research entry. Animal, laboratory, community, or vendor regimens must not be converted into personal dosing instructions.

Dose
Not established on this profile
Frequency
Not established on this profile
Cycle
Not established on this profile
Storage
Follow the exact supplier or authorized product documentation; requirements vary by formulation
Open peptide calculator →

Combination risks

Interactions

Evidence status

No independently verified interaction table is available here for Sermorelin(Sermorelin acetate). Interaction risk depends on identity, formulation, medicines, supplements, and health conditions.

Do not infer compatibility

Being listed beside another compound does not mean that combining them is safe or effective.

Evidence-informed overview

What to Expect

Evidence boundary

Research indications describe topics studied in the literature; they do not predict an individual outcome.

Clinical monitoring

Where an authorized medicinal use exists, expectations and monitoring should come from the current product label and treating clinician.

Risk overview

Side Effects & Safety

The safety profile of Sermorelin(Sermorelin acetate) cannot be inferred from category or molecular identity alone. Research-only materials are not medicines and should not be used in humans.

Verification

Quality Checklist

  1. Confirm exact chemical identity, sequence, salt form, and concentration.
  2. Require a batch-specific certificate of analysis with named test methods and results.
  3. Check manufacturer, lot, expiry, tamper evidence, and documented chain of custody.
  4. For laboratory work requiring sterility, verify sterility and endotoxin testing separately from purity.

Clear answers

Frequently Asked Questions

Is Sermorelin(Sermorelin acetate) approved for personal use?

This catalogue does not identify an authorized personal-use indication. Treat it as research information unless a current local regulator says otherwise.

Why is no dose listed?

A dose is shown only when it has been checked against a current authoritative prescribing label. Speculative or community regimens are intentionally excluded.

Do research indications prove effectiveness?

No. They organize literature topics and evidence signals; they are not treatment recommendations or guarantees.

Source trail

References

  1. The effects of intranasal insufflation of growth hormone releasing factor analogue GRF 1-29 NH2 on growth hormone secretion in children with short statureLaron, Z., et al. · Clinical Endocrinology · 1988
  2. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old menCorpas, E., et al. · Journal of Clinical Endocrinology & Metabolism · 1992
  3. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapyGeref International Study Group · Journal of Clinical Endocrinology & Metabolism · 1996
  4. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and womenVittone, J., et al. · Journal of Clinical Endocrinology & Metabolism · 1997
  5. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?Walker, R.F. · Clinical Interventions in Aging · 2006

View the structural source profile ↗